Skip to main content

Table 3 Serum zinc concentrations, BMI and characteristics of migraine attacks at baseline and 8 weeks after the intervention in migraine patients who received either zinc supplement or placebo

From: Zinc supplementation affects favorably the frequency of migraine attacks: a double-blind randomized placebo-controlled clinical trial

  Zinc groupa Placebo groupb t df P-value*
Baseline Week 8 Change Baseline Week 8 Change
BMI (kg/m2) 24.36 ± 4.19 24.21 ± 4.07 −0.14 ± 0.72 25.50 ± 4.91 25.25 ± 5.33 −0.25 ± 1.65 0.36 78 0.71
Zinc (μg/dL) 85.41 ± 12.87 89.52 ± 12.22 4.11 ± 5.46c 84.20 ± 11.65 87.07 ± 12.26 2.87 ± 7.77a 0.82 78 0.41
Headache severityd 7.22 ± 1.14 5.47 ± 1.78 −1.75 ± 1.79c 6.80 ± 0.93 6.00 ± 1.50 −0.80 ± 1.57a − 2.51 78 0.01
Attacks frequency (month) 8.80 ± 6.16 6.25 ± 4.38 − 2.55 ± 4.32c 9.45 ± 5.39 9.02 ± 6.37 − 0.42 ± 4.24 − 2.22 78 0.02
Attacks duration (hour) 17.67 ± 13.59 13.92 ± 9.90 −3.75 ± 7.91c 22.85 ± 16.47 18.65 ± 14.47 − 4.20 ± 12.04a 0.19 78 0.84
HDRe 151.67 ± 138.87 94.15 ± 117.42 − 57.52 ± 91.64c 198.00 ± 138.98 165.45 ± 155.59 − 32.55 ± 129.22 − 0.99 78 0.32
  1. Abbreviation: BMI body mass index, HDR headache diary result, VAS visual analog scale
  2. All values are presented as mean (SD)
  3. aReceived zinc capsule containing 220 mg zinc sulfate one time per day
  4. bReceived placebo capsule containing lactose one time per day
  5. cSignificant reduction throughout the trial: obtained from paired-sample t-test
  6. dMeasured by VAS that ranked headache severity from 1 to 10
  7. eDetermined by formula: frequency × duration
  8. *Obtained from independent sample t-test for the comparison of changes